At the recommendation of an independent data monitoring committee, J&J’s Janssen decided to stop the MACiTEPH trial in chronic thromboembolic pulmonary hypertension due to futility.
https://www.pharmalive.com/wp-content/uploads/2023/09/Johnson-and-Johnson-Spain.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-07 10:10:442023-09-07 10:10:44J&J terminates Phase III study of blockbuster Opsumit in pulmonary hypertension
